Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody: A Case Report

• Published in: Internal Medicine p. 8772-21
• Main Authors: Ono, Ryohei, Iwai, Yuta, Yamazaki, Tatsuro, Takahashi, Hidehisa, Hori, Yasuhiko, Fukushima, Kenichi, Saotome, Takashi
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 19.03.2022
• Subjects: anti-striated antibody; anti-titin antibody; anti-voltage-gated potassium channel Kv1.4 antibody; immune checkpoint inhibitors; immune-related adverse events; nivolumab; anti-voltage-gated potassium channel Kv1.4 antibody; anti-titin antibody; immune checkpoint inhibitors; nivolumab; anti-striated antibody; immune-related adverse events
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.8772-21

Immune checkpoint inhibitors (ICIs) are complicated by immune-related adverse events (irAEs), such as myositis, myocarditis, and myasthenia gravis (MG). Anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody are anti-striated antibodies that are frequently detected in MG patients with myositis and/or myocarditis. However, the clinical relationship between positive anti-striated antibodies and irAEs of ICIs remains unknown. We herein report a case of nivolumab-induced myositis and myocarditis with positive anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody in a patient with non-small-cell lung cancer. We also review reported cases of positive anti-striated antibodies related to irAEs of ICIs.